Search

Boehringer Ingelheim annouces 2020 BVDzero Case Awards

Boehringer Ingelheim is announcing the 2020 ‘BVDzero Case Awards’ are now open for applications. The bi-annual awards reflect the long-term commitment to promoting the health and well-being of farm animals.

Uniting to stop rabies: a global and local endeavor

By collaborating together, we can stop rabies. Read how we are breaking down barriers through the power of partnerships to fight this deadly disease

License deal with A*STAR to develop cancer antibodies

Phase 1 start for novel triple agonist obesity treatment

Boehringer and Gubra announce Phase 1 study of BI 3034701, a long-acting, next generation, first-in-class triple agonist peptide for obesity treatment

emperor-reduced-chmp-positive-opinion

CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction

Acute Ischaemic Stroke

Vaccine prevent calf diarrhea

Fencovis® is the first vaccine to prevent calf diarrhea caused by E. coli F5 and bovine rotavirus and reduce severity of calf diarrhea caused by bovine coronavirus

Living with type 2 diabetes

People living with type 2 diabetes often suffer a degree of stigma. Learn from Jurjen de Lange what it takes to live a good life despite the disease.

PRRS vaccine celebrates 25 years in Europe

Boehringer Ingelheim celebrates 25 years to combat PRRS in Europe

EMA authorization for Reprocyc ParvoFLEX

Boehringer Ingelheim obtains EMA authorization for Reprocyc® ParvoFLEX, a new porcine parvovirus vaccine

Winners of the 2019 European PRRS Research Award

Winners of the 2019 European PRRS Research Award announced.

Launch of Frontline flagship store on Tmall

Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.

New indications NexGard, NexGard SPECTRA and Broadline

New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA

antibiotic resistance one health veterinary medicine

Antimicrobial resistance is a major global threat to the health of humans and animals alike. Learn about challenges and solutions here.

ArisGlobal acquires Boehringer Ingelheim technology

Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal

The GPP Charter

The GPP Charter defines a collaborative approach to identifying common goals for the GPP community

T-cell engagers: Reawakening T-cells to fight cancer

Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform

The Unwearable Collection - The GPP patient experience

The Unwearable Collection™ is a fashion line based on the experiences of patients living with generalized pustular psoriasis, designed by Bart Hess.

GastroGard the first imported equine drug in China

GastroGard® approved as the first imported equine drug in China. Boehringer Ingelheim officially starts equine health business in China.

Approval for Aservo EquiHaler equine asthma therapy

Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy

Groundbreaking oncology research zongertinib

Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio

The Unwearable Collection™ Evolution

Get ready for the next stage of The Unwearable Collection™

cat feline diabetes medication treatment eu approval

Boehringer Ingelheim receives approval for SENVELGO® in Europe: the first oral liquid medication for diabetic cats

Inauguration of new global center for veterinary vaccine R&D

Inauguration of a new global hi-tech centre for biological research and development in Lyon.

2018 Animal Welfare Medals

2018 Animal Welfare Medals: Boehringer Ingelheim recognizes outstanding research in cattle, equine, swine, as well as small animals and pet categories

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers